Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesImpact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting
European Journal of Cancer Care, 09/04/09
Jordan K et al. – Specific pretreatment QoL parameters are associated with the risk to develop PCNV. Thus, in addition to other established risk factors for PCNV, patients should be screened for these QoL factors in order to improve the control of PCNV and facilitate the selection of appropriate, individualised anti–emetic prophylaxes.
Related Articles
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Supportive Care in Cancer, 11/10/09
Relevance Score: 43%
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
Cancer, 10/20/09
Relevance Score: 43%
Supplemental oxygen and the incidence of perioperative nausea and vomiting in cesarean sections under subarachnoid block
Revista Brasileira de Anestesiologia, 10/05/09
Relevance Score: 43%
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy
Journal of Clinical Oncology, 10/08/09
Relevance Score: 42%
Prophylaxis of postoperative nausea and vomiting in morbidly obese patients undergoing laparoscopic gastroplasties: a comparative study among three methods
Revista Brasileira de Anestesiologia, 10/05/09
Relevance Score: 42%
Today in Adverse Drug Reactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain
Journal of Orthopaedics and Traumatology, 11/24/09
Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies
British Journal of Clinical Pharmacology, 11/24/09
Appraising the post-marketing safety of medicines: A description of national and international pharmacovigilance with a focus on medicines used in chronic pain
Current Anaesthesia and Critical Care, 11/24/09
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09
Sponsor
Article Search
Sponsor